Journal
STEM CELL REVIEWS AND REPORTS
Volume 6, Issue 3, Pages 398-404Publisher
SPRINGER
DOI: 10.1007/s12015-010-9145-2
Keywords
Parkinson's Disease; iPS; Treatment; Reprogramming
Funding
- National Program of Basic Research of China [2006CB500706, 2007CB947900, 2010CB945200]
- National Natural Science Fund [30872729, 30971031]
- Shanghai Key Discipline Program [S30202]
- Program for Outstanding Medical Academic Leader [LJ 06003]
Ask authors/readers for more resources
More recently, reprogramming of somatic cells to an embryonic stem cell-like state presents a milestone in the realm of stem cells, making it possible to derive all cell types from any patients bearing specific genetic mutations. With the development of induced pluripotent stem (iPS) cells, we are now able to use the derivatives of iPS cells to study the mechanisms of disease and to perform drug screening and toxicology testing. In addition, differentiated iPS cells are now close to be used in clinical practice. Here we review the progress of iPS technique and the possible application in the area of Parkinson's disease treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available